Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
本发明涉及选择性取代的
喹啉化合物,其作为Toll样受体7和/或8的拮抗剂或
抑制剂,并且它们在制备有效的药物组合物中的应用用于治疗系统性红斑狼疮(SLE)和狼疮性肾炎。